DOCSLIB.ORG

PTSD Nightmares: Prazosin and Atypical Antipsychotics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PTSD Nightmares: Prazosin and Atypical Antipsychotics Savvy Psychopharmacology PTSD nightmares: Prazosin and atypical antipsychotics Rebecca L. Graham, PharmD, Susan G. Leckband, RPh, BCPP, and Rene A. Endow-Eyer, PharmD, BCPP r. S, a 45-year-old veteran, was diag- PTSD occurs in approximately 19% of nosed with posttraumatic stress disor- Vietnam war combat veterans1 and 14% der (PTSD) 18 years ago after a tour of of service members returning from Iraq M 2 duty in the Persian Gulf. He had combat-related and Afghanistan. PTSD symptoms are flashbacks triggered by the smell of gasoline or classified into clusters: intrusive/re- smoke from a fire, was easily startled, and began experiencing; avoidant/numbing; and to isolate himself socially. However, his symp- hyperarousal.3 Nightmares are part of the Vicki L. Ellingrod, toms improved when he started volunteering at intrusive/re-experiencing cluster, which is PharmD, BCPP, FCCP his local Veterans Affairs Medical Center. After he Criterion B in DSM-IV-TR. See this article Series Editor lost his job 3 years ago, Mr. S started experiencing at CurrentPsychiatry.com for a descrip- flashbacks. He was irritable, easily startled, and tion of DSM-IV-TR PTSD criteria. Among avoided things that reminded him of his time in PTSD patients, 50% to 70% report PTSD- the Persian Gulf. His psychiatrist prescribed ser- associated nightmares.4 Despite adequate traline, titrated to 200 mg/d. The drug reduced treatment targeted to improve PTSD’s core the severity of his avoidance and hyperarousal symptoms, symptoms such as sleep distur- symptoms and improved his mood. bances or nightmares often persist. During a clinic visit, Mr. S says he is doing Nightmares and other sleep disturbanc- well and can fall asleep at night but is having es are associated with significant distress recurring nightmares about traumatic events and daytime impairment and can interfere that occurred during combat. These night- with PTSD recovery4-8 by disrupting sleep- mares wake him up and have become more dependent processing of emotional experi- frequent, occurring once per night for the ences and causing repeated resensitization past month. Mr. S says he has been watch- to trauma cues (Table 1, page 60).8 ing more news programs about conflicts in Few randomized controlled medication Afghanistan and Iraq since the nightmares trials specifically address PTSD-related began. His psychiatrist starts quetiapine, 50 mg at bedtime for 7 nights then 100 mg Practice Points at bedtime, but after 6 weeks Mr. S says his • Prazosin is recommended as a first- nightmares continue. line therapy for nighttime PTSD symptoms, such as nightmares or Dr. Graham is a Second-Year Psychiatric Pharmacy Resident, sleep disturbances—especially among Discuss this article at Veterans Affairs San Diego Healthcare System (VASDHS); veterans—because of superior long-term www.facebook.com/ Ms. Leckband is a Clinical Psychiatric Pharmacist Specialist, effectiveness. CurrentPsychiatry VASDHS, and Assistant Clinical Professor through Skaggs School of Pharmacy and Pharmaceutical Sciences and • Risk of metabolic syndrome, which Department of Psychiatry, University of California, San has been reported with low-dose Diego; and Dr. Endow-Eyer is Psychiatric Clinical Pharmacy Specialist, VASDHS, and Assistant Clinical Professor through atypical antipsychotics used for treating Skaggs School of Pharmacy and Pharmaceutical Sciences and insomnia, limits their use for PTSD-related Department of Psychiatry, University of California, San Diego, nightmares. Current Psychiatry San Diego, CA. Vol. 11, No. 6 59 Savvy Psychopharmacology Table 1 with an average of 3 mg at bedtime and a starting dose of 1 mg. Prazosin is the only Psychosocial consequences agent recommended in the AASM’s Best of sleep disruption in PTSD Practice Guide for treating PTSD-related 11 Increased reactivity to emotional cues nightmares. Compromised ability to function in social and occupational roles Atypical antipsychotics Negative psychiatric outcomes, including Atypical antipsychotics have been used suicidal ideation or worsening of depression to reduce nightmares in PTSD; however, or psychosis most of the evidence from studies evaluat- Interference of natural recovery from trauma ed in the AASM’s Best Practice Guide were exposure considered to be low quality.11 Quetiapine Repeated resensitization to trauma cues and ziprasidone were not included in Neurocognitive deficits the AASM review. Visit this article at Neuroendocrine abnormalities CurrentPsychiatry.com for a table review- PTSD: posttraumatic stress disorder ing the evidence for atypical antipsychot- Source: Adapted from reference 8 Clinical Point ics for treating PTSD nightmares. Prazosin reduced Comparing prazosin and quetiapine. A trauma nightmares nightmares. Most PTSD studies do not historical prospective cohort study of 237 and improved sleep examine sleep outcomes as a primary veterans with PTSD receiving prazosin or quality and global measure, and comprehensive literature re- quetiapine for nighttime PTSD symptoms clinical status more views could not offer evidence-based rec- demonstrated that although the 2 drugs ommendations.9,10 The American Academy have similar efficacy (defined as symp- than placebo of Sleep Medicine (AASM) also noted a tomatic improvement) for short-term, paucity of PTSD studies that identified 6-month treatment (61% vs 62%; P = .54), nightmares as a primary outcome mea- a higher percentage of patients continued sure.11 See this article at CurrentPsychiatry. prazosin long-term (3 to 6 years) than com for a list of recommended medication those taking quetiapine (48% vs 24%; P < options for PTSD-associated nightmares. .001).23 Twenty-five percent of patients tak- ing quetiapine switched to prazosin dur- CASE CONTINUED ing the study, and approximately one-half Medication change, improvement of these patients remained on prazosin After reviewing AASM’s treatment recommen- until the study’s end. Only 8% of prazo- dations, we prescribe prazosin, 1 mg at bedtime sin patients switched to quetiapine, and for 7 nights, then increase by 1 mg at bedtime none continued this therapy until study each week until Mr. S’s nightmares improve. He end.23 Patients in the quetiapine group reports a substantial improvement in nightmare were more likely to discontinue the drug severity and frequency after a few weeks of treat- because of lack of efficacy (13% vs 3%; P = ment with prazosin, 5 mg at bedtime. .03) and adverse effects (35% vs 18%; P = .008), specifically sedation (21% vs 2%; P Prazosin < .001) and metabolic effects (9% vs 0%; P Prazosin is an α1-adrenergic receptor an- = .014), compared with prazosin. Although Visit this article at tagonist with good CNS penetrability. The this trial may be the only published com- CurrentPsychiatry.com rationale for reducing adrenergic activity parison study of prazosin and quetiapine, for a list of medication to address intrusive PTSD symptoms has its methodological quality has been ques- options for PTSD nightmares been well documented.12,13 In open-label tioned, which makes it difficult to draw trials,14-18 a chart review,19 and placebo- definitive conclusions. controlled trials,20-22 prazosin reduced Metabolic syndrome—elevated diastol- trauma nightmares and improved sleep ic blood pressure, increased waist circum- quality and global clinical status more ference, and low high-density lipoprotein than placebo (Table 2). In these studies, cholesterol—is common among PTSD pa- Current Psychiatry 60 June 2012 prazosin doses ranged from 1 to 20 mg/d, tients treated with antipsychotics.24 This Savvy Psychopharmacology Table 2 RCTs of prazosin for trauma-related nightmares Study Design Patients Results Raskind 20-week, double- 10 Vietnam veterans Prazosin was superior to placebo on scores et al, blind, placebo- with chronic PTSD on the recurrent distressing dreams item 200320 controlled, and severe trauma- and difficulty falling/staying asleep item of crossover study related nightmares the CAPS and change in PTSD severity and (mean dose 9.5 functional status on the CGI-C mg/d at bedtime) Raskind 8-week, placebo- 40 veterans with Prazosin was superior to placebo in reducing et al, controlled, parallel chronic PTSD, trauma nightmares and improving sleep 200721 study (mean dose distressing trauma quality and global clinical status; prazosin 13.3 ± 3 mg/d in nightmares, and also shifted dream characteristics of trauma- the evening) sleep disturbance related nightmares to those typical of normal dreams Taylor 7-week, 13 outpatients with Prazosin significantly increased total sleep et al, randomized, chronic civilian time and REM sleep time; reduced trauma- 200822 placebo-controlled, trauma PTSD, related nightmares, distressed awakenings, Clinical Point crossover trial frequent nightmares, and total PCL-C scores; improved CGI-I (mean dose 3.1 ± and sleep scores; and changed PDRS scores toward Evidence 1.3 mg) disturbance normal dreaming CAPS: Clinician-Administered PTSD Scale; CGI-C: Clinical Global Impression of Change; CGI-I: Clinical Global Impression of supporting atypical Improvement; PCL-C: PTSD Checklist-Civilian; PDRS: PTSD Dream Rating Scale; PTSD: posttraumatic stress disorder; RCTs: randomized controlled trials; REM: rapid eye movement antipsychotics to reduce nightmares in PTSD is considered syndrome may be caused by medications, 4. Wittmann L, Schredl M, Kramer M. Dreaming in posttraumatic stress disorder: a critical review of phenomenology, to be low quality lifestyle factors, or long-term overactiva- psychophysiology and treatment.
Load more

Recommended publications
  • Table 2. 2012 AGS Beers Criteria for Potentially
    Table 2. 2012 AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults Strength of Organ System/ Recommendat Quality of Recomm Therapeutic Category/Drug(s) Rationale ion Evidence endation References Anticholinergics (excludes TCAs) First-generation antihistamines Highly anticholinergic; Avoid Hydroxyzin Strong Agostini 2001 (as single agent or as part of clearance reduced with e and Boustani 2007 combination products) advanced age, and promethazi Guaiana 2010 Brompheniramine tolerance develops ne: high; Han 2001 Carbinoxamine when used as hypnotic; All others: Rudolph 2008 Chlorpheniramine increased risk of moderate Clemastine confusion, dry mouth, Cyproheptadine constipation, and other Dexbrompheniramine anticholinergic Dexchlorpheniramine effects/toxicity. Diphenhydramine (oral) Doxylamine Use of diphenhydramine in Hydroxyzine special situations such Promethazine as acute treatment of Triprolidine severe allergic reaction may be appropriate. Antiparkinson agents Not recommended for Avoid Moderate Strong Rudolph 2008 Benztropine (oral) prevention of Trihexyphenidyl extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease. Antispasmodics Highly anticholinergic, Avoid Moderate Strong Lechevallier- Belladonna alkaloids uncertain except in Michel 2005 Clidinium-chlordiazepoxide effectiveness. short-term Rudolph 2008 Dicyclomine palliative Hyoscyamine care to Propantheline decrease Scopolamine oral secretions. Antithrombotics Dipyridamole, oral short-acting* May
    [Show full text]
  • Appendix A: Potentially Inappropriate Prescriptions (Pips) for Older People (Modified from ‘STOPP/START 2’ O’Mahony Et Al 2014)
    Appendix A: Potentially Inappropriate Prescriptions (PIPs) for older people (modified from ‘STOPP/START 2’ O’Mahony et al 2014) Consider holding (or deprescribing - consult with patient): 1. Any drug prescribed without an evidence-based clinical indication 2. Any drug prescribed beyond the recommended duration, where well-defined 3. Any duplicate drug class (optimise monotherapy) Avoid hazardous combinations e.g.: 1. The Triple Whammy: NSAID + ACE/ARB + diuretic in all ≥ 65 year olds (NHS Scotland 2015) 2. Sick Day Rules drugs: Metformin or ACEi/ARB or a diuretic or NSAID in ≥ 65 year olds presenting with dehydration and/or acute kidney injury (AKI) (NHS Scotland 2015) 3. Anticholinergic Burden (ACB): Any additional medicine with anticholinergic properties when already on an Anticholinergic/antimuscarinic (listed overleaf) in > 65 year olds (risk of falls, increased anticholinergic toxicity: confusion, agitation, acute glaucoma, urinary retention, constipation). The following are known to contribute to the ACB: Amantadine Antidepressants, tricyclic: Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Nortriptyline, Trimipramine and SSRIs: Fluoxetine, Paroxetine Antihistamines, first generation (sedating): Clemastine, Chlorphenamine, Cyproheptadine, Diphenhydramine/-hydrinate, Hydroxyzine, Promethazine; also Cetirizine, Loratidine Antipsychotics: especially Clozapine, Fluphenazine, Haloperidol, Olanzepine, and phenothiazines e.g. Prochlorperazine, Trifluoperazine Baclofen Carbamazepine Disopyramide Loperamide Oxcarbazepine Pethidine
    [Show full text]
  • Commonly Prescribed Psychotropic Medications
    COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications* Start: IR-100 mg bid X 4d then ↑ to 100 mg tid; SR-150 mg qam X 4d then ↑ to 150 mg Contraindicated in seizure disorder because it decreases seizure threshold; stimulating; not good for treating anxiety disorders; second Bupropion (Wellbutrin) bid; XL-150 mg qam X 4d, then ↑ to 300 mg qam. Range: 300-450 mg/d. line TX for ADHD; abuse potential. ¢ (IR/SR), $ (XL) Citalopram (Celexa) Start: 10-20 mg qday,↑10-20 mg q4-7d to 30-40 mg qday. Range: 20-60 mg/d. Best tolerated of SSRIs; very few and limited CYP 450 interactions; good choice for anxious pt. ¢ Duloxetine (Cymbalta) Start: 30 mg qday X 1 wk, then ↑ to 60 mg qday. Range: 60-120 mg/d. More GI side effects than SSRIs; tx neuropathic pain; need to monitor BP; 2nd line tx for ADHD. $ Escitalopram (Lexapro) Start: 5 mg qday X 4-7d then ↑ to 10 mg qday. Range 10-30 mg/d (3X potent vs. Celexa). Best tolerated of SSRIs, very few and limited CYP 450 interactions. Good choice for anxious pt. $ Fluoxetine (Prozac) Start: 10 mg qam X 4-7d then ↑ to 20 mg qday. Range: 20-60 mg/d. More activating than other SSRIs; long half-life reduces withdrawal (t ½ = 4-6 d). ¢ Mirtazapine (Remeron) Start: 15 mg qhs. X 4-7d then ↑ to 30 mg qhs. Range: 30-60 mg/qhs. Sedating and appetite promoting; Neutropenia risk (1 in 1000) so avoid in immunosupressed patients.
    [Show full text]
  • Meta-Analysis of the Efficacy of Treatments for Posttraumatic Stress Disorder Bradley V
    META-ANALYSIS Meta-Analysis of the Efficacy of Treatments for Posttraumatic Stress Disorder Bradley V. Watts, MD, MPH; Paula P. Schnurr, PhD; Lorna Mayo, MD, MPH; Yinong Young-Xu, PhD; William B. Weeks, MD, MBA; and Matthew J. Friedman, MD, PhD ABSTRACT treatments for posttraumatic stress disorder (PTSD) have Many 1 2 Objective: Posttraumatic stress disorder (PTSD) is been developed over the past 2 decades. , The treatments an important mental health issue in terms of the include a variety of psychotherapies, medications, and somatic and number of people affected and the morbidity and complementary therapies. The most commonly studied types of functional impairment associated with the disorder. psychotherapy are cognitive-behavioral therapies (CBTs), such as The purpose of this study was to examine the prolonged exposure, 3,4 cognitive processing therapy,5, 6 and cognitive efficacy of all treatments for PTSD. therapy,7,8 along with eye movement desensitization and reprocessing.9, 10 Data Sources: PubMed, MEDLINE, PILOTS, and Most of the research has focused on individual treatment, although PsycINFO databases were searched for randomized there have been some studies of group-based treatment as well. 11,12 The controlled clinical trials of any treatment for PTSD most commonly studied medications are antidepressants, particularly in adults published between January 1, 1980, and selective serotonin reuptake inhibitors (SSRIs). Atypical antipsychotic April 1,2012, and written in the English language. medications also have been studied relatively often, although to a far The following search terms were used: post-traumatic 1 3 141 5 lesser extent than antidepressants. , , stress disorders, posttraumatic stress disorder, PTSD, combat disorders, and stress disorders, post-traumatic.
    [Show full text]
  • Current P SYCHIATRY
    Current p SYCHIATRY N ew Investigators Tips to manage and prevent discontinuation syndromes Informed tapering can protect patients when you stop a medication Sriram Ramaswamy, MD Shruti Malik, MBBS, MHSA Vijay Dewan, MD Instructor, department of psychiatry Foreign medical graduate Assistant professor Creighton University Department of psychiatry Omaha, NE University of Nebraska Medical Center Omaha, NE bruptly stopping common psychotropics New insights on psychotropic A —particularly antidepressants, benzodi- drug safety and side effects azepines, or atypical antipsychotics—can trigger a discontinuation syndrome, with: This paper was among those entered in the 2005 • rebound or relapse of original symptoms Promising New Investigators competition sponsored • uncomfortable new physical and psycho- by the Neuroleptic Malignant Syndrome Information Service (NMSIS). The theme of this year’s competition logical symptoms was “New insights on psychotropic drug safety and • physiologic withdrawal at times. side effects.” To increase health professionals’ awareness of URRENT SYCHIATRY 1 C P is honored to publish this peer- the risk of these adverse effects, this article reviewed, evidence-based article on a clinically describes discontinuation syndromes associated important topic for practicing psychiatrists. with various psychotropics and offers strategies to NMSIS is dedicated to reducing morbidity and anticipate, recognize, and manage them. mortality of NMS by improving medical and psychiatric care of patients with heat-related disorders; providing
    [Show full text]
  • Prazosin: Preliminary Report and Comparative Studies with Other
    298 BRITISH MEDICAL JOURNAL 1 1 MAY 1974 Prazosin: Preliminary Report and Comparative Studies with Other Antihypertensive Agents Br Med J: first published as 10.1136/bmj.2.5914.298 on 11 May 1974. Downloaded from GORDON S. STOKES, MICHAEL A. WEBER British Medical Journal, 1974, 2, 298-300 bilirubin. One patient had minimal grade 3 hypertensive ocu- lar fundus changes, 10 had grade 1 or 2 changes, and four had normal fundi. Serum crea-tinine concentration was normal in Summary every patient. A diagnosis of uncomplicated essential hypertension was In a group of 14 hypertensive patients a 10-week course made in 12 patients. In two other patients pyelographic of treatment with prazosin 3-7 5 mg/day produced a signifi- evidence of analgesic nephropathy was found. The remaining cant reduction in mean blood pressure without serious side patient had essential hypertension and stable angina pectoris. effects. The fall in diastolic pressure exceeded the response After at least two baseline blood pressure readings, taken mm more to a placebo by 10 Hg or in 9 patients. The average when patients were recumbent and standing, treatment was decrease in diastolic pressure was similar to that produced started with prazosin, 1-mg capsules by mouth, three times or by methyldopa 750 mg/day propranolol 120-160 mg/day daily. Thereafter the patient visited the clinic at intervals of was but the fall in systolic pressure comparatively smaller, one to three weeks. At each visit blood pressure was meas- that the consistent with reported experimental work showing ured to the nearest 5 mm Hg with an Accoson sphygmomo- drug causes vasodilatation.
    [Show full text]
  • (PTSD) Executive Summary
    Comparative Effectiveness Review Number 92 Effective Health Care Program Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD) Executive Summary Background Effective Health Care Program Posttraumatic stress disorder (PTSD) is a mental disorder that may develop The Effective Health Care Program following exposure to a traumatic was initiated in 2005 to provide event. According to the 4th edition of valid evidence about the comparative the “Diagnostic and Statistical Manual effectiveness of different medical of Mental Disorders: DSM-IV-TR,”1 interventions. The object is to help the essential feature of PTSD is the consumers, health care providers, development of characteristic and others in making informed symptoms following exposure to a choices among treatment alternatives. traumatic stressor. PTSD is characterized Through its Comparative Effectiveness by three core symptom clusters: Reviews, the program supports (1) reexperiencing, (2) avoidance or systematic appraisals of existing numbing (or both), and (3) hyperarousal. scientific evidence regarding The full DSM-IV-TR criteria are listed treatments for high-priority health in Table A. conditions. It also promotes and generates new scientific evidence by Examples of traumatic events include identifying gaps in existing scientific military combat, motor vehicle evidence and supporting new research. collisions, violent personal assault, The program puts special emphasis being taken hostage, a terrorist attack, on translating findings into a variety torture, natural or human-caused of useful formats for different disasters, and, in some cases, being stakeholders, including consumers. diagnosed with a life-threatening illness.1 PTSD develops in up to a third of The full report and this summary are individuals who are exposed to extreme available at www.effectivehealthcare.
    [Show full text]
  • Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice
    pharmaceuticals Article Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice Geng-Ruei Chang 1,* , Po-Hsun Hou 2,3, Wei-Cheng Yang 4, Chao-Min Wang 1 , Pei-Shan Fan 1, Huei-Jyuan Liao 1 and To-Pang Chen 5,* 1 Department of Veterinary Medicine, National Chiayi University, 580 Xinmin Road, Chiayi 60054, Taiwan; [email protected] (C.-M.W.); [email protected] (P.-S.F.); [email protected] (H.-J.L.) 2 Department of Psychiatry, Taichung Veterans General Hospital, 1650 Taiwan Boulevard (Section 4), Taichung 40705, Taiwan; [email protected] 3 Faculty of Medicine, National Yang-Ming University, 155 Linong Street (Section 2), Taipei 11221, Taiwan 4 School of Veterinary Medicine, National Taiwan University, 1 Roosevelt Road (Section 4), Taipei 10617, Taiwan; [email protected] 5 Division of Endocrinology and Metabolism, Show Chwan Memorial Hospital, 542 Chung-Shan Road (Section 1), Changhua 50008, Taiwan * Correspondence: [email protected] (G.-R.C.); [email protected] (T.-P.C.); Tel.: +886-5-2732946 (G.-R.C.); +886-4-7256166 (T.-P.C.) Abstract: Doxepin is commonly prescribed for depression and anxiety treatment. Doxepin-related disruptions to metabolism and renal/hepatic adverse effects remain unclear; thus, the underlying mechanism of action warrants further research. Here, we investigated how doxepin affects lipid Citation: Chang, G.-R.; Hou, P.-H.; change, glucose homeostasis, chromium (Cr) distribution, renal impairment, liver damage, and fatty Yang, W.-C.; Wang, C.-M.; Fan, P.-S.; liver scores in C57BL6/J mice subjected to a high-fat diet and 5 mg/kg/day doxepin treatment for Liao, H.-J.; Chen, T.-P.
    [Show full text]
  • Olanzapine-Induced Acute Pancreatitis and New Diabetes Mellitus
    Open Journal of Psychiatry, 2012, 2, 110-112 OJPsych http://dx.doi.org/10.4236/ojpsych.2012.22015 Published Online April 2012 (http://www.SciRP.org/journal/ojpsych/) Case report: Olanzapine-induced acute pancreatitis and new diabetes mellitus Erik Monasterio1*, Ruchi Bhalla2, Andrew McKean3 1Department of Psychological Medicine, University of Otago, Christchurch, New Zealand 2Hammersmith and Fulham Mental Health Unit, West London Mental Health NHS Trust, London, UK 3Hillmorton Hospital, Christchurch, New Zealand Email: *[email protected] Received 29 December 2011; revised 31 January 2012; accepted 15 February 2012 ABSTRACT criteria and required application from a psychiatrist for a patient who had been trialled unsuccessfully on risperi- The aim of this case study is to review the literature done or required treatment with olanzapine short acting and report the first published case of olanzapine-in- intra-muscular injection [4]. In June 2011, significantly duced acute pancreatitis in New Zealand. A case re- cheaper generic versions of olanzapine were introduced port of acute pancreatitis with new onset diabetes and the special authority criteria for olanzapine with- mellitus secondary to olanzapine in a 42-year-old male, drawn [5]. We aim to highlight lesser known and poten- in the absence of medical risk factors is reported. tially fatal side effects through our case report. Eleven previous case reports of olanzapine induced acute-pancreatitis were identified in the literature. A 2. CASE REPORT 42-year-old male was diagnosed with acute pancreati- tis and new diabetes mellitus induced by olanzapine. Mr. X is a 42 year old man who had come into contact Although rare, pancreatitis is associated with use of with mental health services on many occasions during some atypical antipsychotic medications.
    [Show full text]
  • The American Journal Of
    The American Journal of Psychiatry Residents’ Journal July 2015 Volume 10 Issue 7 Inside IN THIS ISSUE 2 New Formats and New Opportunities: The Time to Get Involved is “Now”! Rajiv Radhakrishnan, M.B.B.S., M.D. 3 Prevention of Posttraumatic Stress Disorder: Predicting Response to Trauma Jennifer H. Harris, M.D. 7 Weight Gain in Patients With Schizophrenia: A Recipe For Timely Intervention Ammar El Sara, M.B.Ch.B. 10 Hyperprolactinemia and Antipsychotics: Update for the Training Psychiatrist Stephanie Pope, M.D. 13 A Clinical Case Conference on Spiritual Growth and Healing Elizabeth S. Stevens, D.O. This issue of the Residents’ Journal features a variety of topics. Jennifer H. Har- ris, M.D., discusses prevention of posttraumatic stress disorder, with an overview 15 Priapism: A Rare but Serious of various responses to trauma. Ammar El Sara, M.B.Ch.B., presents a review of Side Effect of Trazodone clinically applicable evidence-based interventions targeting obesity in schizophre- Kamalika Roy, M.D. nia patients. Stephanie Pope, M.D., examines antipsychotic-induced hyperprolac- 17 Classifying Psychopathology: tinemia, including variables affecting prolactin and clinical implications. Elizabeth Mental Kinds and Natural Kinds S. Stevens, D.O., discusses several psychological, social, and spiritual developmen- Reviewed by Aaron J. Hauptman, tal frameworks in a clinical case conference. Kamalika Roy, M.D., presents a case M.D. of priapism as a side effect of trazodone in a middle-aged patient. Lastly, Aaron J. Hauptman, M.D., offers his review of the book Classifying Psychopathology: Mental 18 Residents’ Resources Kinds and Natural Kinds. Editor-in-Chief Associate Editors Editors Emeriti Rajiv Radhakrishnan, M.B.B.S., M.D.
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]